Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors ...Middle East

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 25, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next...

Hence then, the article about harbour biomed announces nmpa approval of ind for combination therapy of next gen anti ctla 4 antibody for treatment of nsclc and solid tumors was published today ( Friday 26/02/2021 - 06:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors )

Also on site :

• Macy’s Valley Fair shoppers thwart Rolex watch thieves
• RCB-W vs UPW-W Dream11 Prediction, Dream11 Playing XI, Today Match 5, WPL 2026
• Motional puts AI at center of robotaxi reboot as it targets 2026 for driverless service